IP Library Granted Patent US 8,163,915
Granted Patent B2
US 8,163,915 · App. 12/052,061 · Granted Apr 24, 2012

4-substituted azaadamantane derivatives and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,163,915
App. No.
12/052,061
Granted
Apr 24, 2012
Kind
B2
Abstract

The invention relates to compounds that are 4-substituted azaadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.

Claims (21)

1. A compound of formula (I)

wherein Y 1 is a bond, —N(R x )—C(O)—, —O—, —N(R x )—C(O)—N(R y )—, —O—C(O)—, or —N(R z )—;

A is aryl, heteroaryl, arylalkyl, or heteroarylalkyl wherein the aryl, heteroaryl, the aryl moiety of arylalkyl, and the heteroaryl moiety of the heteroarylalkyl are each independently unsubstituted or substituted; and

R x , R y , and R z , at each occurrence, are each independently hydrogen, alkyl, or haloalkyl;

or a pharmaceutically acceptable salt or amide thereof.

2. The compound according to claim 1 , wherein Y 1 is —N(R x )—C(O)— or —O—C(O)—, wherein Y 1 is attached to A of formula (I) through —C(O)— moiety, or a pharmaceutically acceptable salt or amide thereof.

3. The compound according to claim 1 wherein Y 1 is —N(R x )—C(O)— and A is aryl or heteroaryl, or a pharmaceutically acceptable salt or amide thereof.

4. The compound according to claim 1 wherein Y 1 is —N(R x )—C(O)— and A is arylalkyl or heteroarylalkyl, or a pharmaceutically acceptable salt or amide thereof.

5. The compound according to claim 1 wherein Y 1 is —O—, or a pharmaceutically acceptable salt or amide thereof.

6. The compound according to claim 1 wherein Y 1 is —O— and A is aryl or heteroaryl, or a pharmaceutically acceptable salt or amide thereof.

7. The compound according to claim 1 wherein Y 1 is —O— and A is arylalkyl or heteroarylalkyl, or a pharmaceutically acceptable salt or amide thereof.

8. The compound according to claim 1 selected from the group consisting of

1-azatricyclo[3.3.1.1 3,7 ]decan-4-one O-2-naphthyloxime;

1-azatricyclo[3.3.1.1 3,7 ]decan-4-one O-(pentafluorobenzyl)oxime;

1-azatricyclo[3.3.1.1 3,7 ]decan-4-one O-(4-chlorophenyl)oxime;

1-azatricyclo[3.3.1.1 3,7 ]decan-4-one O-(6-chloropyridin-3-yl)oxime;

N′-1-azatricyclo[3.3.1.1 3,7 ]dec-4-ylidene-1H-indole-3-carbohydrazide; and

1-azatricyclo[3.3.1.1 3,7 ]decan-4-one O-benzyloxime;

or a pharmaceutically acceptable salt or amide thereof.

9. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt or amide thereof, in combination with one or more pharmaceutically acceptable carriers.

10. The pharmaceutical composition of claim 9 further comprising one or more atypical antipsychotics.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030235/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2008
From: BUNNELLE, WILLIAM H.
To: ABBOTT LABORATORIES
Reel/Frame 021173/0490 →